Congenital myasthenic syndromes: beta adrenergic receptor agonist treatment


  • David Beeson oxford university



Congenital myasthenic syndrome, Ephedrine, albuterol, DOK7, COLQ, CHRNE


Acetylcholinesterase inhibitors, such as pyridostigmine, are the standard symptomatic treatment for myasthenia gravis, and so have naturally been applied to the genetic forms of myasthenia, termed congenital myasthenic syndromes (CMS). Although effective for many CMS in others there was no clear response and in some it was positively harmful. Now, with greater understanding of the mutations and molecular mechanisms underlying CMS, treatments can be tailored for the specific syndrome and depending on diseases severity and patient response this can include utilizing different combinations of the drugs. In CMS, over the last 15-20 years b2-adrenergic receptor agonists have moved from occasional use to a mainstream medication. Many cases show life-transforming improvement both when the b2-adrenergic receptor agonists are used alone or in combination. Here we feature how the identification of DOK7-CMS first highlighted the consistent benefit of b2-adrenergic receptor agonists as medication and how it’s application to many different CMS subtypes evolved.  The molecular pathogenic mechanisms for many CMS subtypes are now established and this report will also discuss a hypothetical rationale for which forms of CMS are likely to benefit from the b2-adrenergic receptor agonists.


Metrics Loading ...


Download data is not yet available.


Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015;14(4):420-34.

Ramdas S, Beeson D. Congenital myasthenic syndromes: where do we go from here? Neuromuscul Disord. 2021 Oct;31(10):943-954. PMID: 34736634

Lee M, Beeson D, Palace J. Therapeutic strategies for congenital myasthenic syndromes. Ann N Y Acad Sci. 2018 Jan;1412(1):129-136. PMID: 29381222

Ohno K, Tsujino A, Brengman JM, Harper CM, Bajzer Z, Udd B, et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2017-22. PMID: 11172068

Harper, C.M. & A. Engel. 1998. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann.Neurol. 43:480–484.35. PMID: 9546329

Harper, C.M., T. Fukodome & A. Engel. 2003. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology 60:1710–1713. PMID: 12771277

Edgeworth, H. 1930. A report of progress on the use of ephedrine in a case of myasthenia gravis. JAMA 94:1136

Edgeworth H. The effect of ephedrine in the treatment of myasthenia gravis. JAMA 1933;100:1401.

Rowland LP. Prostigmine-responsiveness and the diagnosis of myasthenia gravis. Neurology 1955; 5:612–623

Engel, AG. The therapy of congenital myasthenic syndromes. Neurotherapeutics 2007; 4:186 –197 PMID: 17395135

Beeson D, Higuchi O, Palace J, Cossins J, Spearman H, Maxwell S, et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science. 2006 Sep 29;313(5795):1975-8. PMID: 16917026

Lashley D, Palace J, Jayawant S, Robb S, Beeson D. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology. 2010 May 11;74(19):1517-23. PMID: 20458068

Slater CR, Fawcett PR, Walls TJ, Lyons PR, Bailey SJ, Beeson D, et al. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain. 2006 Aug;129(Pt 8):2061-76. PMID: 16870884

Palace J, Lashley D, Newsom-Davis J, Cossins J, Maxwell S, Kennett R et al. Clinical features of the DOK7 neuromuscular junction synaptopathy. Brain. 2007 Jun;130:1507-15. PMID: 17452375

Jaretzki A, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Sanders DB. Myasthenia gravis: recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16 –23. PMID: 10891897

Liewluck T, Selcen D, Engel AG. 2011. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and DOK-7 myasthenia. Muscle Nerve 44: 789–794 PMID: 21952943

Schara U, Barisic N, Deschauer M, Lindberg C, Straub V, Strigl-Pill N, et al. Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord. 2009 Dec;19(12):828-32. PMID: 19837590

Burke G, Allen D, Arunachalam R, Beeson D, Hammans S. A treatable muscle disease. Pract Neurol. 2009 Aug;9(4):233-6. PMID: 19608775

Lorenzoni PJ, Scola RH, Kay CS, Filla L, Miranda AP, Pinheiro JM, et al. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation. J Neurol Sci. 2013 Aug 15;331(1-2):155-7. PMID: 23790237

Burke G, Hiscock A, Klein A, Niks EH, Main M, Manzur AY, et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord. 2013 Feb;23(2):170-5. PMID: 23219351

Tsao CY. Effective treatment with albuterol in DOK7 Congenital Myasthenic Syndrome in Children Pediatr Neurol. 2016; 54:85-7. PMID: 26552645

Sanes JR, Lichtman JW. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat Rev Neurosci. 2001 Nov;2(11):791-805. PMID: 11715056

Bergamin E, Hallock PT, Burden SJ, Hubbard SR. The cytoplasmic adaptor protein Dok7 activates the receptor tyrosine kinase MuSK via dimerization. Mol Cell. 2010 Jul 9;39(1):100-9. PMID: 20603078

Selcen D, Ohkawara B, Shen XM, McEvoy K, Ohno K, Engel AG. Impaired Synaptic Development, Maintenance, and Neuromuscular Transmission in LRP4-Related Myasthenia. JAMA Neurol. 2015 Aug;72(8):889-96. PMID: 26052878

Hallock PT, Xu CF, Park TJ, Neubert TA, Curran T, Burden SJ. Dok-7 regulates neuromuscular synapse formation by recruiting Crk and Crk-L. Genes Dev. 2010 Nov 1;24(21):2451-61. PMID: 21041412

Clausen L, Cossins J, Beeson D. Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders.J Neuromuscul Dis. 2018;5(2):231-240 .PMID: 29865088

Bestue-Cardiel M, Sáenz de Cabezón-Alvarez A, Capablo-Liesa JL, López-Pisón J, Peña-Segura JL, Martin-Martinez J, Engel AG. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology. 2005 Jul 12;65(1):144-6. PMID: 16009904

Mihaylova V, Müller JS, Vilchez JJ, Salih MA, Kabiraj MM, D'Amico A et al. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain. 2008 Mar;131(Pt 3):747-59. PMID: 18180250

Chan SH, Wong VC, Engel AG. Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol. Pediatr Neurol. 2012 Aug;47(2):137-40. PMID: 22759693

Ohno K, Brengman J, Tsujino A, Engel AG. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9654-9. PMID: 9689136

Karmouch J, Dobbertin A, Sigoillot S, Legay C. Developmental consequences of the ColQ/MuSK interactions Chem Biol Interact. 2013 Mar 25;203(1):287-91. PMID: 23089045

Misgeld T, Kummer TT, Lichtman JW, Sanes JR. Agrin promotes synaptic differentiation by counteracting an inhibitory effect of neurotransmitter. Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):11088-93. doi: PMID: 16043708

Kummer TT, Misgeld T, Sanes JR. Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost. Curr Opin Neurobiol. 2006 Feb;16(1):74-82. PMID: 16386415

Engel AG, Lambert EH, Santa T. Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure. Neurology. 1973 Dec;23(12):1273-81. PMID: 4357114

Vincent A, Cull-Candy SG, Newsom-Davis J, Trautmann A, Molenaar PC, Polak RL. Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases. Muscle Nerve. 1981 Jul-Aug;4(4):306-18. PMID: 7254233

Vanhaesebrouck AE, Webster R, Maxwell S, Rodriguez Cruz PM, Cossins J, Wickens J, et al.. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure. Brain. 2019 Dec 1;142(12):3713-3727. PMID: 31633155

Cossins J, Webster R, Maxwell S, Burke G, Vincent A, Beeson D. A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition. Hum Mol Genet. 2004 Dec 1;13(23):2947-57. PMID: 15471888

McMacken GM, Spendiff S, Whittaker RG, O'Connor E, Howarth RM, Boczonadi V, et al. Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome. Hum Mol Genet. 2019 Jul 15;28(14):2339-2351. PMID: 31220253

Webster RG, Vanhaesebrouck AE, Maxwell SE, Cossins JA, Liu W, Ueta R, et al. Effect of salbutamol on neuromuscular junction function and structure in a mouse model of DOK7 congenital myasthenia. Hum Mol Genet. 2020 Aug 11;29(14):2325-2336. PMID: 32543656

Bukharaeva E, Khuzakhmetova V, Dmitrieva S, Tsentsevitsky A Adrenoceptors Modulate Cholinergic Synaptic Transmission at the Neuromuscular Junction.Int J Mol Sci. 2021 Apr 28;22(9):4611. PMID: 33924758

Straka T, Schröder C, Roos A, Kollipara L, Sickmann A, Williams MPI, Hafner M, Khan MM, Rudolf R. Regulatory Function of Sympathetic Innervation on the Endo/Lysosomal Trafficking of Acetylcholine Receptor. Front Physiol. 2021 Mar 11;12:626707. PMID: 33776791






MGFA International Conference Proceedings

How to Cite

Beeson, D. (2023). Congenital myasthenic syndromes: beta adrenergic receptor agonist treatment. RRNMF Neuromuscular Journal, 4(3).